Which Psychedelic Therapy Is Best for Anxiety?

What Is the Most Effective Psychedelic Therapy for Anxiety? At a Glance

In terms of raw effectiveness, meaning the magnitude of symptom relief seen in the peer-reviewed research so far, LSD is currently the front-runner. Psilocybin and ketamine therapy also show strong effects; where the options really diverge is the type of anxiety each has been tested for and how accessible each one is today.

• ‍LSD has produced the largest anxiety reduction reported in a peer-reviewed generalized anxiety trial. In a single Phase 2b study, one dose reduced anxiety symptoms by about two-thirds, and 47.5% of patients reached remission. That comes from one mid-stage trial, and the treatment is available only through research (Robison et al., 2025).¹‍
• Psilocybin has shown very strong results as well, but primarily in people facing cancer or end-of-life illness. In cancer patients, clinician-rated anxiety has fallen by roughly two-thirds (Griffiths et al., 2016).⁶ For everyday generalized anxiety, its measured effect on the GAD-7 has been much smaller (Hood and Elkins, 2026).²‍
• Ketamine therapy lands in the same broad range, and it is the one available to most people today. In Mindbloom's largest study, 56.1% of patients responded and average anxiety scores fell by about half, across a far larger group of people than every psychedelic anxiety trial combined (Mathai et al., 2024).⁴‍
• MDMA has been studied for social anxiety and trauma, and its research base in generalized anxiety is smaller. In a small pilot in autistic adults with social anxiety, about 75% responded (Danforth et al., 2018).⁷ That does not mean it is ineffective, only that it has not been tested as rigorously for anxiety as the others here.

These trials used different scales, thresholds, and populations, so the percentages are not directly comparable. The table further down lays out each option, and the sections after it go deeper.

What Is Psychedelic Therapy for Anxiety?

Psychedelic therapy pairs a mind-altering medicine with structured psychological support. In a session, the medicine produces an altered state that can surface new insights while also opening what is thought to be a window of heightened neuroplasticity, a period when the brain more readily forms new connections and loosens entrenched patterns of worry. The container around the dose, preparation beforehand, a supervised dosing experience, and integration afterward, is what turns those insights and that added flexibility into lasting change. The medicine is only part of it; the therapy built around it does much of the work.

A common first question is whether ketamine even counts as a psychedelic. On a molecular level, it is a dissociative anesthetic that acts on the brain's glutamate system, while the classic psychedelics, psilocybin and LSD, act mainly on serotonin receptors. In practice, however, ketamine produces altered, dreamlike states that overlap enough with the classic psychedelic experience that it is often described as psychedelic-style, and it is used within the broader field of psychedelic-assisted therapy. So both things are true at once: ketamine is not a classic serotonergic psychedelic, and it is the psychedelic-adjacent medicine most people can actually access for anxiety today.

How Psychedelics May Ease Anxiety in the Brain

The leading explanation is that these compounds briefly open a window of increased neuroplasticity, a period in which the brain forms new connections more readily and entrenched patterns of worry become easier to shift. Classic psychedelics do this mainly through serotonin 2A receptors, while ketamine works through the glutamate system and appears to support the growth of new synaptic connections. In both cases, the theory is that the medicine loosens rigid thinking long enough for the psychological work to land differently.

This is still an emerging area of science, and much of the mechanistic detail comes from preclinical research rather than large human studies. For a fuller explanation, see our psychedelic therapy guide.

The Main Types of Psychedelic Therapy for Anxiety, Compared

The table below maps the leading research for each option, the most significant studies rather than a complete catalog of everything published. Read it as a map, not a leaderboard. The figures come from different trials using different anxiety scales in different populations, and every number is a within-group change from the start of treatment, not a placebo-subtracted result. A higher number can simply reflect a more sensitive scale or an easier population, so this is not a ranking.

Psilocybin for Anxiety: Strongest Evidence in Serious Illness

Psilocybin, the active compound in magic mushrooms, has the most encouraging psychedelic anxiety data, but almost all of it comes from people facing cancer or other life-threatening illness rather than generalized anxiety. In the strongest of these trials, a single high dose alongside supportive therapy reduced clinician-rated anxiety by roughly two-thirds, with about 83% of patients responding and 57% to 63% in remission at six months (Griffiths et al., 2016).⁶

A 2024 Cochrane review of this literature concluded that classic psychedelics may reduce anxiety and depression in people with life-threatening disease, while rating the certainty of the evidence as low (Schipper et al., 2024).⁸

The picture for generalized anxiety, the everyday, chronic worry most people mean by "anxiety," is much thinner. When researchers pooled the trials that measured psilocybin on the self-report GAD-7, the average improvement was about 3 points, below the threshold generally considered clinically meaningful (Hood and Elkins, 2026).² A dedicated generalized-anxiety trial of psilocybin has not yet been peer-reviewed, so its results should be read with caution. That does not mean psilocybin is ineffective for anxiety, only that the evidence outside of serious illness is still evolving.

LSD for Anxiety: The Largest Reported Effect So Far

LSD has produced the single strongest peer-reviewed psychedelic result in generalized anxiety. In a Phase 2b trial, a single dose reduced clinician-rated anxiety by about 65% at four weeks, with roughly 65% of patients responding and 47.5% reaching remission at twelve weeks, durable off one dose (Robison et al., 2025).¹

It also comes with real caveats. It is a single mid-stage trial that has not yet been repeated, and it is not available outside of research. Two older, smaller pilots tested LSD for anxiety related to life-threatening illness and pointed in a similar direction. LSD is one of the most promising psychedelics for generalized anxiety on paper, though the timeline for its public availability as an anxiety treatment remains unclear.

MDMA and Ayahuasca for Anxiety: Earlier-Stage Evidence

MDMA is primarily a treatment being studied for trauma and social anxiety rather than generalized anxiety. Its clearest anxiety result comes from a small pilot in autistic adults with severe social anxiety, where about 75% responded on a social-anxiety scale (Danforth et al., 2018).⁷ A separate pilot in people with life-threatening illness did not reach statistical significance. Future trials may show promising results for generalized anxiety; for now, MDMA's evidence base is strongest in social anxiety and trauma.

Ayahuasca is earlier still. The one controlled trial in a diagnosed anxiety population, in social anxiety, did not significantly reduce anxiety compared with placebo (dos Santos et al., 2022).⁹ A single trial that misses its mark does not mean a treatment does not work, and the evidence base is still maturing, but ayahuasca is best understood as emerging rather than established for anxiety.

Ketamine Therapy for Anxiety: Available Now and Widely Studied

Ketamine is the one compound in this category that is legally available and delivered at scale in the United States today. It is an FDA-approved anesthetic that clinicians prescribe off-label for mental health conditions, which is why ketamine therapy for anxiety does not require a clinical trial to access. Rather than acting on serotonin like the classic psychedelics, it works through the brain's glutamate system and appears to support the growth of new synaptic connections.

It also has the largest published anxiety evidence base of any option here, and it is the most-studied of these compounds in people diagnosed with anxiety disorders (Feulner et al., 2023).¹⁰ Across three peer-reviewed studies, ketamine therapy has reported structured GAD-7 outcomes in roughly 10,000 patients, more than the combined randomized clinical-trial literature for the other psychedelics in anxiety.³⁻⁵ Those three studies point the same way:

• Mindbloom's peer-reviewed subcutaneous study: 80.0% of patients saw clinically meaningful improvement across a six-session course, average GAD-7 scores fell from about 13 to 6, 60.6% of patients responded, and 29.6% reached remission (Parks et al., 2026).⁵
• The program's largest sublingual study: average anxiety scores fell from 15.2 to 7.6, a reduction of about half, with 56.1% of patients responding and 28.8% reaching remission (Mathai et al., 2024).⁴
• A supporting sublingual study: a 62.9% response rate and 31.3% remission (Hull et al., 2022).³

Reported ketamine response rates sit squarely within the range of the psychedelic anxiety trials, comparable to the 65% reported for LSD and above the unpublished psilocybin generalized-anxiety readout. Ketamine therapy does not claim to be the single most effective molecule for anxiety, and no head-to-head trial has ever compared these treatments. What sets it apart is a combination of the size of its real-world evidence base, defined treatment course, and accessibility. Our guide breaks down which types of anxiety ketamine works best for.

Psychedelic Therapy vs. Conventional Anxiety Treatments

Most people considering psychedelics for anxiety have already tried first-line treatment. Here, the useful contrast is not effect size but speed and structure.

Set side by side, the three families of treatment differ most in how they are delivered and how quickly they work:

• First-line medication (SSRIs and SNRIs): the standard starting point, and effective for many people. Even so, roughly one in three patients with generalized anxiety does not respond to first-line medication (Strawn et al., 2018).¹¹
• Psychedelic therapies: across the trials, reported response rates generally sit above the roughly 47% pooled response rate for CBT in generalized anxiety, and they arrive far faster. Relief comes from a single supervised session for LSD and psilocybin, or a course of a few weeks for ketamine therapy, against the twelve or more weeks a course of CBT typically takes (Loerinc et al., 2015).¹² LSD reported about 65% response in its Phase 2b trial (Robison et al., 2025),¹ and ketamine therapy reports 56% to 63% across its published studies (Hull et al., 2022; Mathai et al., 2024; Parks et al., 2026).³⁻⁵
• Benzodiazepines: a different niche. Modern guidelines classify them as second-line and appropriate for short-term use, and the largest network meta-analysis of anxiety medications described them as effective but poorly tolerated (Slee et al., 2019).¹³

The psychedelic and psychedelic-style therapies are also built around producing measurable change over a defined course or session rather than daily symptom suppression. Higher reported response rates, faster timelines, and that change-focused design are the reasons psychedelic therapy can be a strong option for people who have not found what they were looking for in first-line care. It is not a replacement for first-line treatment, and among these options ketamine therapy is the one available today.

Is Psychedelic Therapy for Anxiety Safe?

In research and clinical settings, these treatments are delivered with screening beforehand and supervision during and after the session, which is a large part of why their safety record has been reasonably good. In the trials, the most common effects have been temporary and tied to the dosing session itself:

• LSD: dose-dependent visual perceptual changes, nausea, and headache, most of them mild to moderate, transient, and confined to the dosing day (Robison et al., 2025).¹
• Psilocybin and MDMA: a similar pattern of short-lived, session-related effects, including temporary increases in blood pressure and heart rate and anxiety during the experience.
• Ketamine: session effects such as dissociation and nausea. Across Mindbloom's peer-reviewed studies, side effects were infrequent and generally mild, affecting roughly 3% to 5% of patients (Hull et al., 2022).³ Serious adverse events occurred in fewer than 0.1% of cases (Parks et al., 2026).⁵

Individual results may vary.

These treatments are not appropriate for everyone. Across the psychedelic and ketamine studies, researchers screened out broadly similar groups, and common exclusions include:

• A personal or family history of schizophrenia, bipolar disorder, or other psychotic conditions
• Significant or unstable cardiovascular disease, including uncontrolled high blood pressure
• Current active suicidal ideation
• Pregnancy

Any legitimate provider or trial will screen for these before starting treatment. A program that does not ask is a warning sign.

How to Access Psychedelic Therapy for Anxiety

For anxiety, the practical dividing line is not which compound looks best on paper. It is what you can legally receive.

• Ketamine therapy is available today by prescription. Mindbloom delivers it through a clinician-supervised at-home program that runs through telehealth and requires a support person present during sessions, while in-clinic infusions are offered by ketamine clinics in most metropolitan areas.
• Psilocybin and LSD are Schedule I and investigational. The only legal route to psilocybin-assisted or LSD-assisted therapy is a clinical trial. Oregon and Colorado run state-regulated adult psilocybin programs, but these are not medical treatment for anxiety.
• MDMA-assisted therapy is also trial-only. The FDA declined to approve MDMA for PTSD in 2024, and it is not approved for any anxiety condition.

One point of confusion is worth clearing up: esketamine (Spravato), the nasal-spray form of ketamine, is FDA-approved for treatment-resistant depression, not for anxiety. The ketamine used in at-home anxiety programs is racemic ketamine, prescribed off-label, which is legal and widely used. For most people asking which psychedelic therapy they can actually start for anxiety, ketamine therapy is the answer available now.

What the Research Still Needs to Answer

The honest gaps are worth stating plainly. No trial has ever compared these treatments head to head, so any ranking is inferred from separate studies using different scales in different populations. The psychedelic trials that report the highest remission figures, LSD and the psilocybin cancer studies, are small, single-dose, and run on clinician-rated scales, sometimes with acknowledged difficulty keeping participants unaware of their assignment. The field also lacks a validated way to translate one anxiety scale into another to compare these results cleanly.

Larger, better-controlled trials in generalized anxiety are still needed for psilocybin and LSD, and the evidence for MDMA and ayahuasca in anxiety remains very uncertain (Schipper et al., 2024).⁸ The most defensible reading today is the one this article leads with: reported outcomes across the better-studied options land in a broadly similar range, and the clearest practical difference is that ketamine therapy is proven at scale and available now.